openFDA
Cure8 regulatory brief
Dexamethasone FDA label update (2026-09-04)
Medications
Corticosteroids
Steroids
Regulatory Update
Patients On Biologics
Adult patients
Clinicians
Inflammatory bowel disease
Why This Matters
Dexamethasone is a systemic corticosteroid with an official label that still includes short‑term use to "tide the patient over a critical period" in Crohn's disease (regional enteritis) and ulcerative colitis.
Changes to the label or clarifying dosing guidance may affect how clinicians consider steroid use in IBD flare management.
Who Should Pay Attention
Adults with IBD considering or prescribed systemic steroids, caregivers, and clinicians who manage acute IBD flares or steroid tapering.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA (DailyMed) label record for dexamethasone describing indications, dosing guidance, and administration details. The label lists gastrointestinal uses including "regional enteritis and ulcerative colitis" and gives oral and parenteral dosing ranges, guidance on individualized dosing, and tapering recommendations.
It is a regulatory drug-label update record (not a clinical-trial result or new treatment guideline).
Keep In Mind
This record is the official prescribing information (DailyMed/FDA label). Labels summarize approved uses and standard dosing but do not replace individualized medical advice. Corticosteroids are generally used for short‑term control of flares; long‑term steroid use has known risks and other steroid-sparing therapies are often preferred.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorREMEDYREPACK INC.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedSep 4, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
SOLU-MEDROL FDA label update (2026-07-23)
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid...
Dexamethasone Intensol FDA label update (2026-08-21)
This is the official FDA label text for dexamethasone, so it clarifies approved uses and gives practical dosing and tapering guidance. It explicitly names "regional enteritis and ulcerative colitis," which matters to...
Dexamethasone FDA label update (2026-07-07)
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...